Nash, Jonathan (2017) The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications. In: EMDR Association UK & Ireland Annual Conference 2017, 24th - 25th March 2017, London.
![[img]](/style/images/fileicons/slideshow.png) |
Slideshow (Powerpoint)
EMDR.pptx - Published Version Restricted to Registered users only Download (5MB) | Request a copy |
![[img]](/style/images/fileicons/text.png) |
Text (Slideshow)
EMDR (1).pdf - Published Version Restricted to Registered users only Download (2MB) | Request a copy |
Abstract
Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. The presentation touches on psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. Current US trials of MDMA-assisted psychotherapy and medical marijuana for treatment-resistant PTSD are focussed on as are patent applications for nasal ketamine sprays for the acutely suicidal. The laws and regulatory procedures governing current clinical research and likely future licensing are considered.
| Item Type: | Conference or Workshop Item (Lecture) |
|---|---|
| Uncontrolled Keywords: | PTSD, psychedelic medicines, legal and policy implications |
| Subjects: | B200 Pharmacology, Toxicology and Pharmacy M200 Law by Topic |
| Department: | Faculties > Business and Law > Northumbria Law School |
| Depositing User: | Jonathan Nash |
| Date Deposited: | 04 Sep 2017 09:42 |
| Last Modified: | 01 Aug 2021 07:22 |
| URI: | http://nrl.northumbria.ac.uk/id/eprint/31695 |
Actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
